The Multiple Sclerosis Research Highlights pages of the National Institute of Neurological Disorders and Stroke (a member of the U.S. government National Institutes of Health) provides extensive text-only information about multiple sclerosis, including emerging treatments, clinical trials of new drugs, genetic research, and future research directions. This site is especially useful for those looking for information about basic and clinical scientific research on multiple sclerosis.
The National Multiple Sclerosis Society is an inclusive, easy-to-use site, providing general information about multiple sclerosis (in both English and Spanish); treatments and therapies; current research; national and world-wide chapters; support groups; and MS clinics. The site also provides news about recent publications on MS and information for health professionals.
The World of Multiple Sclerosis comes from the Multiple Sclerosis International Federation. In an attractive graphic format, it provides FAQs in more than a dozen languages; the complete text of several MSIF publications; links to other MS Society sites; other resources and news; and a section for professionals.
While our understanding of relapsing remitting disease and
treatment options have expanded enormously in recent years, understanding the
mechanism of secondary and primary progressive MS, including the
neurodegenerative aspects of these diseases, remains a central question.
Imaging Early MS New MRI Technique Reveals Potential Biomarker of Inflammation and Target for Less Toxic Multiple Sclerosis Treatments 2012 12 10 An Interview with John
Physicians first noted the presence of cognitive impairment in patients with multiple sclerosis (MS) more than 160 years ago, yet it took clinicians until 2001 to codify a standard test to measure cognitive function. We now know that cognitive impairment occurs in up to 65 percent of people with MS and usually lessens their ability to remember previously learned information. So far, trials of drugs formulated to treat cognitive impairment have failed, but the authors remain optimistic that new approaches to diagnosis and drug development could lead to effective therapies in the future.
Two studies assess the effectiveness of a new pill for multiple sclerosis.
Multiple Sclerosis (MS) is a common neurologic condition that usually affects individuals between the ages of 15 and 45. It is an autoimmune disease that attacks the myelin sheaths of nerve fibers of both the brain and spinal cord.